Trial Profile
A trial of NSI 566 in patients with acute spinal cord injury in South Korea.
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs NSI 566 (Primary)
- Indications Spinal cord injuries
- Focus Therapeutic Use
- Sponsors Palisade Bio; Seneca Biopharma
- 20 Oct 2014 New trial record